Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

The Role of Biomarkers in Bladder Cancer

June 1st 2016

Measuring Response in Non-Muscle Invasive Bladder Cancer

June 1st 2016

Approaches in High-Risk Non-Muscle Invasive Bladder Cancer

June 1st 2016

Check Point Inhibition in Muscle-Invasive Bladder Cancer

June 1st 2016

Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer

June 1st 2016

First-Line Options in Muscle-Invasive Bladder Cancer

June 1st 2016

Abiraterone Plus Prednisone in CRPC: Factors to Consider

June 1st 2016

CRPC: Patient Selection in AR-Directed Therapies

June 1st 2016

Therapeutic Options in Metastatic CRPC

June 1st 2016

Safety of Low-Dose Steroids with Abiraterone in Prostate Cancer

June 1st 2016

Potential Predictive Markers in Prostate Cancer

June 1st 2016

Candidacy for Chemotherapy in Oligometastatic Prostate Cancer

June 1st 2016

Local and Systemic Therapeutic Options in Low-Volume Prostate Cancer

June 1st 2016

Combining Radium-223 With Other Therapies in Prostate Cancer

June 1st 2016

Factors Impacting Treatment Approach in Advanced Prostate Cancer

June 1st 2016

Defining Symptomatic in Prostate Cancer

June 1st 2016

Treatment of Bone Metastases in Prostate Cancer

June 1st 2016

Dr. Scott Tagawa Discusses IMMU-132 in Patients With Urothelial Carcinoma

May 31st 2016

Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the antibody-drug conjugate IMMU-132 for the treatment of patients with metastatic platinum-resistant urothelial cancer.

Dr. Funahashi on Enhanced Activity With Lenvatinib/Everolimus Combo in RCC

May 27th 2016

Yasuhiro Funahashi, MD, senior director, Eisai, discusses a study exploring the enhanced antitumor activity with the combination of lenvatinib (Lenvima) and everolimus (Afinitor) in patients with renal cell carcinoma (RCC).

Dr. Stanley Yap on Sequential Therapy for Muscle-Invasive Bladder Cancer

May 27th 2016

Stanley Yap, MD, assistant professor, urologic oncology, UC Davis Comprehensive Cancer Center, discusses sequential therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer.